JANX vs MGNX
JANX: Janux Therapeutics is a clinical-stage biotech developing tumor-activated T-cell engagers and immunomodulators to treat cancer and autoimmune diseases with reduced toxicity. MGNX: A clinical-stage biotechnology company leveraging proprietary bispecific DART technology and antibody-drug conjugates to develop novel cancer immunotherapies.
Side-by-side fundamentals
| Metric | JANX | MGNX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $18.50 | $3.55 | |
| Market cap | $1.1B | $226M | |
| Net margin FY2025, SEC XBRL | n/a | -49.9% | |
| Operating margin FY2025, SEC XBRL | n/a | -48.7% | |
| ROE FY2025, SEC XBRL | -11.9% | -134.2% | JANX higher |
| ROA FY2025, SEC XBRL | -11.3% | -29.1% | JANX higher |
| Debt / equity as of 2026-09-02 | 0.00 | 3.24 | JANX lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +2.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.5% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.11 | 1.55 | |
| 1-year return as of 2026-10-08 close | -23.6% | +99.4% | MGNX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.